NASDAQ:ESPR Esperion Therapeutics (ESPR) Stock Price, News & Analysis → Millionaire investor and Republican donor makes surprising election prediction (From InvestorPlace) (Ad) Free ESPR Stock Alerts $2.23 +0.04 (+1.83%) (As of 05/13/2024 ET) Add Compare Share Share Today's Range$2.17▼$2.3250-Day Range$1.84▼$3.2452-Week Range$0.70▼$3.40Volume4.42 million shsAverage Volume7.05 million shsMarket Capitalization$422.50 millionP/E RatioN/ADividend YieldN/APrice Target$9.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Esperion Therapeutics alerts: Email Address Esperion Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.40 Rating ScoreUpside/Downside318.5% Upside$9.33 Price TargetShort InterestBearish11.79% of Float Sold ShortDividend StrengthN/ASustainability-2.76Upright™ Environmental ScoreNews Sentiment0.31Based on 43 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.17) to $0.34 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.40 out of 5 starsMedical Sector306th out of 925 stocksPharmaceutical Preparations Industry136th out of 430 stocks 3.2 Analyst's Opinion Consensus RatingEsperion Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageEsperion Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Esperion Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted11.79% of the float of Esperion Therapeutics has been sold short.Short Interest Ratio / Days to CoverEsperion Therapeutics has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Esperion Therapeutics has recently increased by 6.83%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldEsperion Therapeutics does not currently pay a dividend.Dividend GrowthEsperion Therapeutics does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEsperion Therapeutics has received a 53.54% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Ezetimibe", "Clinical research services for pulmonary hearth diseases", and "Bempedoic acid" products. See details.Environmental SustainabilityThe Environmental Impact score for Esperion Therapeutics is -2.76. Previous Next 1.8 News and Social Media Coverage News SentimentEsperion Therapeutics has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 43 news articles for Esperion Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 40 people have searched for ESPR on MarketBeat in the last 30 days. This is a decrease of -44% compared to the previous 30 days.MarketBeat FollowsOnly 10 people have added Esperion Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Esperion Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.00% of the stock of Esperion Therapeutics is held by insiders.Percentage Held by Institutions47.39% of the stock of Esperion Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Esperion Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Esperion Therapeutics are expected to grow in the coming year, from ($0.17) to $0.34 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Esperion Therapeutics is -2.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Esperion Therapeutics is -2.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Esperion Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyAmerica’s worst nightmare?What This Group Has Planned for the 2024 Election Will Shock You Controversial new exposé reveals what’s really going on in America, what it means for your money, and what you must do to protect your assets before it’s too late.Click here to watch this bombshell exposé now. About Esperion Therapeutics Stock (NASDAQ:ESPR)Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.Read More ESPR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ESPR Stock News HeadlinesMay 13 at 2:40 AM | americanbankingnews.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) to Post Q2 2024 Earnings of ($0.16) Per Share, HC Wainwright ForecastsMay 12 at 3:50 AM | americanbankingnews.comHC Wainwright Weighs in on Esperion Therapeutics, Inc.'s FY2026 Earnings (NASDAQ:ESPR)May 11 at 2:16 AM | americanbankingnews.comAnalysts Offer Predictions for Esperion Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:ESPR)May 10, 2024 | globenewswire.comEsperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)May 10, 2024 | americanbankingnews.comHC Wainwright Reiterates "Buy" Rating for Esperion Therapeutics (NASDAQ:ESPR)May 9, 2024 | americanbankingnews.comFY2026 EPS Estimates for Esperion Therapeutics, Inc. Cut by Analyst (NASDAQ:ESPR)May 8, 2024 | msn.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Q1 2024 Earnings Call TranscriptMay 8, 2024 | markets.businessinsider.comEsperion Gains Buy Rating on Strong Sales Growth and Strategic ProgressMay 8, 2024 | americanbankingnews.comEsperion Therapeutics (NASDAQ:ESPR) Given "Buy" Rating at Needham & Company LLCMay 8, 2024 | finance.yahoo.comEsperion Therapeutics Inc (ESPR) Q1 2024 Earnings Call Transcript Highlights: Soaring Revenues ...May 8, 2024 | americanbankingnews.comStock Traders Purchase High Volume of Call Options on Esperion Therapeutics (NASDAQ:ESPR)May 7, 2024 | marketwatch.comEsperion Shares Jump on Strong 1Q Results Above Analyst ExpectationsMay 7, 2024 | finance.yahoo.comEsperion Therapeutics Inc (ESPR) Surpasses Q1 Revenue Forecasts with a 467% IncreaseMay 7, 2024 | investorplace.comESPR Stock Earnings: Esperion Therapeutics Beats EPS, Beats Revenue for Q1 2024May 7, 2024 | investorplace.comWhy Is Esperion Therapeutics (ESPR) Stock Up 13% Today?May 7, 2024 | washingtonpost.comEsperion Therapeutics: Q1 Earnings SnapshotMay 7, 2024 | americanbankingnews.comZacks Research Comments on Esperion Therapeutics, Inc.'s Q1 2026 Earnings (NASDAQ:ESPR)May 7, 2024 | globenewswire.comEsperion Reports First Quarter 2024 Financial ResultsMay 5, 2024 | americanbankingnews.comEsperion Therapeutics (ESPR) Set to Announce Earnings on TuesdayMay 1, 2024 | nasdaq.comEsperion Therapeutics, Inc. Common Stock (ESPR)April 29, 2024 | globenewswire.comEsperion to Participate in Upcoming May Investor ConferencesApril 23, 2024 | finance.yahoo.comEsperion to Report First Quarter 2024 Financial Results on May 7April 21, 2024 | finance.yahoo.com11 Best Low Price Pharma Stocks To Invest InApril 8, 2024 | msn.comEsperion stock jumps as non-statin therapy shows clinical benefits across diverse patient groupsApril 7, 2024 | globenewswire.comEsperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with ObesitySee More Headlines Receive ESPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Esperion Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today5/13/2024Next Earnings (Estimated)8/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ESPR CUSIPN/A CIK1434868 Webwww.esperion.com Phone(734) 887-3903FaxN/AEmployees240Year FoundedN/APrice Target and Rating Average Stock Price Target$9.33 High Stock Price Target$16.00 Low Stock Price Target$4.00 Potential Upside/Downside+318.5%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-209,250,000.00 Net Margins-37.65% Pretax Margin-37.65% Return on EquityN/A Return on Assets-33.44% Debt Debt-to-Equity RatioN/A Current Ratio2.22 Quick Ratio1.78 Sales & Book Value Annual Sales$116.33 million Price / Sales3.63 Cash FlowN/A Price / Cash FlowN/A Book Value($3.85) per share Price / Book-0.58Miscellaneous Outstanding Shares189,460,000Free Float187,565,000Market Cap$422.50 million OptionableOptionable Beta0.89 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Sheldon L. Koenig (Age 58)President, CEO & Director Comp: $1.28MDr. JoAnne Micale Foody FACC (Age 59)M.D., Chief Medical Officer Comp: $856.87kMr. Eric J. Warren R.Ph. (Age 52)Chief Commercial Officer Comp: $718.86kMr. Benjamin Halladay M.B.A. (Age 38)Chief Financial Officer Mr. Glenn P. Brame (Age 66)Chief Technical Operations Officer Mr. Benjamin O. Looker J.D. (Age 42)General Counsel & Corporate Secretary Comp: $550.35kTiffany Aldrich M.B.A.Associate Director of Corporate CommunicationsMs. Betty Jean SwartzChief Business OfficerMore ExecutivesKey CompetitorsPepGenNASDAQ:PEPGRevance TherapeuticsNASDAQ:RVNCAcelyrinNASDAQ:SLRNNeurogeneNASDAQ:NGNELexicon PharmaceuticalsNASDAQ:LXRXView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 3,688,796 shares on 5/10/2024Ownership: 4.660%Tocqueville Asset Management L.P.Bought 39,750 shares on 5/10/2024Ownership: 0.021%Kingsview Wealth Management LLCSold 6,500 shares on 5/9/2024Ownership: 0.013%State Board of Administration of Florida Retirement SystemBought 18,471 shares on 5/9/2024Ownership: 0.010%Bleakley Financial Group LLCSold 8,003 shares on 5/8/2024Ownership: 0.009%View All Insider TransactionsView All Institutional Transactions ESPR Stock Analysis - Frequently Asked Questions Should I buy or sell Esperion Therapeutics stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Esperion Therapeutics in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ESPR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ESPR, but not buy additional shares or sell existing shares. View ESPR analyst ratings or view top-rated stocks. What is Esperion Therapeutics' stock price target for 2024? 5 brokerages have issued 1 year target prices for Esperion Therapeutics' stock. Their ESPR share price targets range from $4.00 to $16.00. On average, they expect the company's share price to reach $9.33 in the next twelve months. This suggests a possible upside of 318.5% from the stock's current price. View analysts price targets for ESPR or view top-rated stocks among Wall Street analysts. How have ESPR shares performed in 2024? Esperion Therapeutics' stock was trading at $2.99 at the beginning of the year. Since then, ESPR shares have decreased by 25.4% and is now trading at $2.23. View the best growth stocks for 2024 here. When is Esperion Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 6th 2024. View our ESPR earnings forecast. How were Esperion Therapeutics' earnings last quarter? Esperion Therapeutics, Inc. (NASDAQ:ESPR) posted its quarterly earnings results on Tuesday, February, 27th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.03. The biopharmaceutical company earned $32.25 million during the quarter, compared to analyst estimates of $26.84 million. During the same period in the previous year, the business posted ($0.76) earnings per share. What ETF holds Esperion Therapeutics' stock? Jacob Forward ETF holds 60,591 shares of ESPR stock, representing 4.36% of its portfolio. What is Tim Mayleben's approval rating as Esperion Therapeutics' CEO? 20 employees have rated Esperion Therapeutics Chief Executive Officer Tim Mayleben on Glassdoor.com. Tim Mayleben has an approval rating of 80% among the company's employees. What other stocks do shareholders of Esperion Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Esperion Therapeutics investors own include ALDW (ALDW), Targa Resources (TRGP), Navios Maritime Partners (NMM), NVIDIA (nvda), Micron Technology (MU), SFL (SFL), Gilead Sciences (GILD), Boeing (BA), Alibaba Group (BABA) and BioMarin Pharmaceutical (bmrn). Who are Esperion Therapeutics' major shareholders? Esperion Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Wasatch Advisors LP (4.82%), Vanguard Group Inc. (4.66%), GSA Capital Partners LLP (0.24%), Susquehanna Fundamental Investments LLC (0.09%), Susquehanna Portfolio Strategies LLC (0.05%) and Tocqueville Asset Management L.P. (0.02%). Insiders that own company stock include Benjamin Looker, Eric Warren, J Martin Carroll, Joanne M Foody, Sheldon L Koenig and Target N V Biotech. View institutional ownership trends. How do I buy shares of Esperion Therapeutics? Shares of ESPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ESPR) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersGuard Against the Coming Financial UpheavalPorter & CompanyElon’s New Device is About to Shock the WorldInvestorPlaceConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressCharles Payne Demystifies OptionsUnstoppable ProsperityThe only AI company you should be looking atBehind the MarketsGold ManiaStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Esperion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
